Nerviano Medical Sciences Srl Announces Rozlytrek® (Entrectinib) Royalty Agreement

- NMS to receive up to $21 Million
- Financing proceeds will be used to advance NMS's proprietary PARP1-selective, non-trapping, brain-penetrant, inhibitor NMS-293, as well as its selective PARP7 inhibitor atamparib

NERVIANO, Italy and NEW YORK, NY, March 31, 2025 - Nerviano Medical Sciences S.r.l. (NMS), and Nerviano Medical Sciences, Inc., (NMS-US) a wholly owned subsidiary of NMS Srl, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, today announced a transaction with a group of investors, including NovaQuest Capital Management.

This transaction enables NMS to monetize a percentage of future Rozlytrek® (entrectinib) royalties, for an amount up to $21 million. Under the terms of the agreement, after a pre-set return on investment is reached by the purchasers, NMS retains all subsequent royalties tied to Rozlytrek® (entrectinib) global net sales.

"This non-dilutive capital infusion enables NMS to support the development of atamparib, a Phase II- ready selective PARP7 inhibitor we recently in-licensed1, as well as NMS' potent, proprietary, brain-penetrant, PARP1-selective inhibitor, NMS-293. We reacquired full rights on the asset2, and we are expanding clinical investigation of NMS-293 beyond glioma, namely in small cell lung cancer and ovarian cancer patients3" said Hugues Dolgos, Pharm.D., Chief Executive Officer, NMS.

"We are delighted to partner with NMS and provide funding to support the continued development of their innovative small molecule and ADC platform pipeline," said Ryan Wooten, Managing Director at NovaQuest. "NMS has brought many innovative oncology therapeutics to market, and we look forward to new products to come."

1. Nerviano Medical Sciences Announces Strategic acquisition of atamparib, a Phase II-ready PARP7 Inhibitor, from Ribon Therapeutics
2. Nerviano Medical Sciences (NMS) to Reacquire World-Wide Rights of NMS-293, a Potent, Highly Selective, Non-Trapping, Brain-Penetrant PARP1 Inhibitor with Promising Clinical Results
3. Nerviano Medical Sciences announces FDA clearance of two INDs for its PARP1-selective, non-trapping inhibitor NMS-293 to start clinical studies in small cell lung cancer and BRCA wild-type ovarian , carcinoma

Advisors
Morgan Stanley & Co. LLC acted as the sole structuring agent.

About NovaQuest Capital Management

NovaQuest Capital Management, located in North Carolina's Research Triangle, is a life science investment firm with a specialization in biopharmaceuticals. Founded in 2010, and with more than $2.5 billion raised across four funds, NovaQuest provides tailored capital solutions that fund innovation in biopharmaceutical development and invests in compelling healthcare companies with products and technologies aimed at helping humans and animals live healthier, longer, more productive lives. Learn more at https://www.novaquest.com/ .

About Nerviano Medical Sciences

Nerviano Medical Sciences S.r.l. (NMS) focuses on discovering and clinically developing small molecule New Chemical Entities (NCEs) for oncology, aiming to deliver first- and best-in-class personalized cancer treatments through innovative mechanisms and novel drug targets. Our pipeline, built from our validated kinase platform, includes projects from early preclinical to clinical stages, advanced both internally and in partnership.
NMS Srl combines biotech agility with big pharma quality, guided by an experienced management team and a skilled staff with global expertise in research, drug discovery, and clinical development. Our capabilities are extended by NMS Group affiliates Accelera (AdMet) and NerPharMa (manufacturing), covering the entire drug development process.
A core strength lies in our renowned kinase inhibitor platform, featuring an extensive chemical library and IP coverage, which has led to discover NCEs targeting NAD-binding pockets, with potential expansion to other NAD-dependent enzymes. Our growing payload-linker platform further enhances our pipeline by enabling next-generation ADC production.
Collaborating globally with academic, clinical, and industry partners, we seek further strategic alliances to develop, commercialize, and expand our product portfolio while exploring in-licensing opportunities for promising clinical assets

For more information, visit https://www.nervianoms.com

About NMS Group

NMS Group is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, recently gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.
NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization.

Media Relations: [email protected]